|
Sep 3
|
Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024
|
|
Jul 30
|
Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference
|
|
Jul 29
|
Neurodegenerative Disease-Focused Anavex Life Sciences' Alzheimer's Candidate Slows Disease Progression By Almost 39%
|
|
Jul 29
|
Anavex seek EMA approval despite shaky pivotal Alzheimer’s trial data
|
|
Jul 28
|
Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference
|
|
Jun 20
|
Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
|
|
May 15
|
Anavex Life Sciences (AVXL) Upgraded to Buy: What Does It Mean for the Stock?
|
|
May 14
|
Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ
|
|
May 10
|
Anavex Life Sciences Corp. (NASDAQ:AVXL) Q2 2024 Earnings Call Transcript
|
|
May 9
|
Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update
|
|
May 2
|
Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024
|
|
Apr 11
|
Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference
|
|
Mar 25
|
Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
|
|
Mar 18
|
Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
|
|
Jan 16
|
Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
|
|
Jan 9
|
Anavex (AVXL): Strong Industry, Solid Earnings Estimate Revisions
|
|
Jan 8
|
5 Small-Cap Stocks to Play the January Effect
|
|
Jan 8
|
Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders
|
|
Dec 20
|
Anavex (AVXL) Rises as CHMP Deems Blarcamesine Eligible for MAA
|
|
Dec 20
|
Anavex Life Sciences Stock Sees RS Rating Jump To 86; Is It One To Watch?
|